Literature DB >> 28237436

Cationic dendritic starch as a vehicle for photodynamic therapy and siRNA co-delivery.

Sarah A Engelberth1, Nadine Hempel2, Magnus Bergkvist3.   

Abstract

Cationic enzymatically synthesized glycogen (cESG) is a naturally-derived, nano-scale carbohydrate dendrite that has shown promise as a cellular delivery vehicle owing to its flexibility in chemical modifications, biocompatibility and relative low cost. In the present work, cESG was modified and evaluated as a vehicle for tetraphenylporphinesulfonate (TPPS) in order to improve cellular delivery of this photosensitizer and investigate the feasibility of co-delivery with short interfering ribonucleic acid (siRNA). TPPS was electrostatically condensed with cESG, resulting in a sub-50nm particle with a positive zeta potential of approximately 5mV. When tested in normal ovarian surface epithelial and ovarian clear cell carcinoma cell culture models, encapsulation of TPPS in cESG significantly improved cell death in response to light treatment compared to free drug alone. Dosages as low as 0.16μM TPPS resulted in cellular death upon illumination with a 4.8J/cm2 light dosage, decreasing viability by 96%. cESG-TPPS was then further evaluated as a co-delivery system with siRNA for potential combination therapy, by charge-based condensation of an siRNA directed at reducing expression of manganese superoxide dismutase (Sod2) as a proof of principle target. Simultaneous delivery of TPPS and siRNA was achieved, reducing Sod2 protein expression to 48%, while maintaining the photodynamic properties of TPPS under light exposure and maintaining low dark toxicity. This study demonstrates the versatility of cESG as a platform for dual delivery of small molecules and oligonucleotides, and the potential for further development of this system in combination therapy applications.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cationic enzymatically synthesized glycogen; Co-delivery; Photodynamic therapy; Sulfonated porphyrin; TPPS; siRNA

Mesh:

Substances:

Year:  2017        PMID: 28237436      PMCID: PMC5396058          DOI: 10.1016/j.jphotobiol.2017.02.013

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  36 in total

1.  Multifunctional organic nanoparticles with aggregation-induced emission (AIE) characteristics for targeted photodynamic therapy and RNA interference therapy.

Authors:  Guorui Jin; Guangxue Feng; Wei Qin; Ben Zhong Tang; Bin Liu; Kai Li
Journal:  Chem Commun (Camb)       Date:  2016-02-14       Impact factor: 6.222

2.  Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine.

Authors:  D Kessel; P Thompson; K Saatio; K D Nantwi
Journal:  Photochem Photobiol       Date:  1987-06       Impact factor: 3.421

3.  Optimization of photodynamic therapy response by survivin gene knockdown in human metastatic breast cancer T47D cells.

Authors:  Ingrid S Cogno; Natalia B Rumie Vittar; Maria Julia Lamberti; Viviana A Rivarola
Journal:  J Photochem Photobiol B       Date:  2011-05-20       Impact factor: 6.252

Review 4.  Photodynamic therapy.

Authors:  T J Dougherty
Journal:  Photochem Photobiol       Date:  1993-12       Impact factor: 3.421

5.  Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study.

Authors:  P Baas; A E Saarnak; H Oppelaar; H Neering; F A Stewart
Journal:  Br J Dermatol       Date:  2001-07       Impact factor: 9.302

6.  Characterization of the self-assembly of meso-tetra(4-sulfonatophenyl)porphyrin (H(2)TPPS(4-)) in aqueous solutions.

Authors:  Javoris V Hollingsworth; Allison J Richard; M Graça H Vicente; Paul S Russo
Journal:  Biomacromolecules       Date:  2011-12-09       Impact factor: 6.988

Review 7.  Photodynamic therapy for nonmelanoma skin cancers. Current review and update.

Authors:  Nathalie C Zeitouni; Allan R Oseroff; Sherry Shieh
Journal:  Mol Immunol       Date:  2003-07       Impact factor: 4.407

8.  Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases.

Authors:  M G Dilkes; E Benjamin; S Ovaisi; A S Banerjee
Journal:  J Laryngol Otol       Date:  2003-09       Impact factor: 1.469

9.  siRNA-mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines.

Authors:  Makito Miyake; Masazumi Ishii; Kiyotaka Kawashima; Tetsuro Kodama; Kokichi Sugano; Kiyohide Fujimoto; Yoshihiko Hirao
Journal:  Photochem Photobiol       Date:  2009-03-20       Impact factor: 3.421

Review 10.  Non-oncologic indications for ALA-PDT.

Authors:  R-M Szeimies; M Landthaler; S Karrer
Journal:  J Dermatolog Treat       Date:  2002       Impact factor: 3.359

View more
  2 in total

Review 1.  Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Authors:  Yuan Zhang; Juhura G Almazi; Hui Xin Ong; Matt D Johansen; Scott Ledger; Daniela Traini; Philip M Hansbro; Anthony D Kelleher; Chantelle L Ahlenstiel
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

2.  The Potential of Nanotechnology in Medically Assisted Reproduction.

Authors:  Mariana H Remião; Natalia V Segatto; Adriana Pohlmann; Silvia S Guterres; Fabiana K Seixas; Tiago Collares
Journal:  Front Pharmacol       Date:  2018-01-11       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.